Abstract

SARS-CoV-2 was firstly identified in december of 2019 in Wuhan, China, being declared pandemic in March of 2020 by the WHO. This disease mobilized the scientific community to develop vaccines to diminish its mortality Chile through the ministry of health adopted a vaccine scheme with the two main vaccines available at that time. These schemes were Coronavax-Coronavax-BNT162b2, and triple-BNT162b2. Methods: Adult donors, vaccinated with Coronavax-Coronavax-BNT162b2, BNT162b2-BNT162b2-BNT162b2 or unvaccinated that got the disease and then recovered were recruited in Santiago and Concepcion. For serum collection, we used a vacutainer with no anticoagulant and collected at least 5 mL of venous blood. Immunoglobulin G against protein N, S1-RBD and neutralizing antibodies were detected using Chemiluminiscent Immunoassay with SNIBE commercial kit for each immunoglobulin. Samples were analyzed using Maglumi X8 detector. Geometrical mean values (GMV), and statistical analysis were calculated using R-Studio Software. Results: Neutralizing antibodies were analyzed, the data showed that got disease and recovered donors have low neutralizing response (GMV 0,54µg/mL), while Coronavax�Coronavax-BNT162b2 and BNT162b2-BNT162b2-BNT162b2 donors have a positive response with a GMV of 10,5 and 23,3µg/mL respectively. IgG gainst S1-RBD was analyzed, all groups have presence of IgG. disease and recovered donors had a GMV of 24,8AU, while Coronavax-Coronavax-BNT162b2 and BNT162b2-BNT162b2-BNT162b2 groups showed a GMV of 289,8 and 258,3AU respectively. But, was no difference between these groups. Conclusion: All of the vaccinations schemes analyzed elicited an immune response; however, the neutralizing response is the one that keep the infection under control. Of the analyzed schemes, triple BNT162b2 showed a better neutralizing response, at least twofold of Coronavax-Coronavax-BNT162b2